Corona Remedies made a strong debut on Dalal Street on Monday, December 15, 2025, with shares opening at ₹1,470 on NSE and ₹1,452 on BSE, against the IPO price of ₹1,062, marking a 38% listing gain.
The ₹655-crore IPO, fully an offer-for-sale, was heavily oversubscribed, reflecting robust investor interest. Grey market data had also suggested strong demand ahead of listing.
The Gujarat-based pharma firm specializes in women’s healthcare and cardiometabolic medicines. Early trading showed sustained gains, indicating positive market sentiment for the stock.